Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Parker Acquires SciLog to Strengthen Single-use System Capability

Published: Friday, August 24, 2012
Last Updated: Thursday, August 23, 2012
Bookmark and Share
Acquisition will allow Parker to deliver an enhanced bioprocessing portfolio.

Parker Hannifin Corporation has announced the acquisition of SciLog Inc, a provider of unique and proprietary single-use technologies and systems for the biopharmaceutical market to support their on-going development as a key supplier to the growing single-use market.

The acquisition will allow Parker to deliver an enhanced bioprocessing portfolio combining filtration and separation expertise, disposable bag systems and automated single-use solutions.

SciLog will be integrated into Parker's Process Filtration Division, which provides high-purity filtration and separation solutions coupled with disposable bags and tubing assemblies for applications such as cell culture media and buffer preparation, product stream filtration and sterile fill finish.

Parker's offering to customers will be enhanced through the addition of SciLog's patented sensor technology for process monitoring and control coupled with unique automation technology from lab to production scale in upstream and downstream processing.

"The addition of SciLog perfectly complements our existing core strengths in filtration and disposable assemblies for the biopharmaceutical market," said Dr Mike Brailsford, General Manager at Parker's Process Filtration Division.

Dr Brailsford continued, "Our customers will now benefit from complete, turnkey solutions that enhance productivity, increase cost-effectiveness and facilitate processing units of operation such as buffer / media prep, virus inactivation etc."

"Today SciLog becomes a global business," said Juliette Schick, CEO and President of SciLog, "With this acquisition SciLog now has a platform in Parker to access global markets, distribution channels and resources to maximize SciLog's single-use product offerings and patent positions."

Parker's expanded capabilities in the biopharmaceutical market will be delivered globally through an extensive and growing global technical support network coupled with customer support centres in over 50 countries.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!